The number of participants reporting AEs in the MAD study
| Placebo | AZD8848 | |
|---|---|---|
| n=2 (%) | n=6 (%) | |
| Participants with any AE | 1 (50.0) | 6 (100.0) |
| Abdominal discomfort | 0 (0.0) | 1 (16.7) |
| Arthralgia | 0 (0.0) | 2 (33.3) |
| Decreased appetite | 0 (0.0) | 2 (33.3) |
| Dizziness | 0 (0.0) | 1 (16.7) |
| Headache | 1 (50.0) | 4 (66.7) |
| Musculoskeletal stiffness | 0 (0.0) | 1 (16.7) |
| Nasopharyngitis | 0 (0.0) | 1 (16.7) |
| Nausea | 0 (0.0) | 2 (33.3) |
| Night sweats | 0 (0.0) | 1 (16.7) |
| Pain | 0 (0.0) | 1 (16.7) |
| Pyrexia | 0 (0.0) | 2 (33.3) |
The adverse events were coded by preferred term according to MedDRA coding. All symptoms were reviewed by the authors from the description provided by the Principal Investigator. From the subjects in the AZD8848 group 4 out of the 6 subjects reported generalized symptoms consisting of one or more of pyrexia, arthralgia, musculoskeletal stiffness, body pain which were considered to represent influenza-like symptoms. AE, adverse event.